Kim Sablich
Director/Board Member en EIGER BIOPHARMACEUTICALS, INC. .
Fortuna: 3 M $ al 31/03/2024
Perfil
Kim Sablich is an Independent Director at Eiger BioPharmaceuticals, Inc. She was previously a Director at AllerGenis LLC from 2018 to 2021, Vice President at GSK Plc from 2015 to 2018, Chief Commercial Officer at Myovant Sciences, Inc. from 2018 to 2020, and Chief Commercial Officer at Myovant Sciences Ltd.
from 2018 to 2020.
She is also currently serving as Executive VP & General Manager-North America at Jazz Pharmaceuticals Plc from 2020 to 2023.
Ms. Sablich received her undergraduate degree from Denison University and her MBA from The Wharton School of the University of Pennsylvania.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
05/06/2023 | 28 478 ( 0.05% ) | 3 M $ | 31/03/2024 | |
20/11/2023 | 200 ( 0.01% ) | 1 001 $ | 31/03/2024 |
Cargos activos de Kim Sablich
Empresas | Cargo | Inicio |
---|---|---|
EIGER BIOPHARMACEUTICALS, INC. | Director/Board Member | 23/04/2021 |
Antiguos cargos conocidos de Kim Sablich.
Empresas | Cargo | Fin |
---|---|---|
JAZZ PHARMACEUTICALS PLC | Corporate Officer/Principal | 31/12/2023 |
AllerGenis LLC
AllerGenis LLC Data Processing ServicesTechnology Services AllerGenis LLC specializes in detecting and managing life-threatening food allergies. AllerGenis is based in Hatfield, PA, and the CEO of the joint venture company is Jim Garner. The company develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. AllerGenis owns and operates a CLIA-certified laboratory and is amassing the world's largest database of phenotypic patient data derived from epitope mapping, clinical history, and patient-reported outcomes. The company was founded in 2017 through a collaboration between Genisphere and Hugh Sampson MD of the Icahn School of Medicine at Mount Sinai. | Director/Board Member | 01/04/2021 |
MYOVANT SCIENCES LTD. | Corporate Officer/Principal | 11/05/2020 |
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Corporate Officer/Principal | 01/05/2020 |
GSK PLC | Corporate Officer/Principal | 01/05/2018 |
Formación de Kim Sablich.
Denison University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
GSK PLC | Health Technology |
JAZZ PHARMACEUTICALS PLC | Health Technology |
EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
Empresas privadas | 3 |
---|---|
Myovant Sciences, Inc.
Myovant Sciences, Inc. Medical SpecialtiesHealth Technology Myovant Sciences, Inc. offers therapeutics for women's health and prostate cancer. The company is headquartered in New York, NY. | Health Technology |
Myovant Sciences Ltd.
Myovant Sciences Ltd. BiotechnologyHealth Technology Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom. | Health Technology |
AllerGenis LLC
AllerGenis LLC Data Processing ServicesTechnology Services AllerGenis LLC specializes in detecting and managing life-threatening food allergies. AllerGenis is based in Hatfield, PA, and the CEO of the joint venture company is Jim Garner. The company develops precision, data-driven diagnostics to help healthcare providers more accurately and safely diagnose, assess, and monitor patients with food allergies. AllerGenis owns and operates a CLIA-certified laboratory and is amassing the world's largest database of phenotypic patient data derived from epitope mapping, clinical history, and patient-reported outcomes. The company was founded in 2017 through a collaboration between Genisphere and Hugh Sampson MD of the Icahn School of Medicine at Mount Sinai. | Technology Services |
- Bolsa de valores
- Insiders
- Kim Sablich